This Article Full Text Full Text (PDF) All Versions of this Article: 91/11/4232    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenbloom, A. L. Articles by Guevara-Aguirre, J. Search for Related Content PubMed PubMed Citation Articles by Rosenbloom, A. L. Articles by Guevara-Aguirre, J. Pubmed/NCBI databases Substance via MeSH Related Collections Metabolism Neuroendocrinology and Pituitary

Reclassification of Insulin-Like Growth Factor I Production and Action Disorders

Division of Endocrinology (A.L.R.), Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida 32608; and Instituto Endocrinologia, Metabolismo y Reproduccion (J.G.-A.), Quito, Ecuador

Address all correspondence and requests for reprints to: Arlan L. Rosenbloom, Children’s Medical Services Center, 1701 Southwest 16th Avenue, Gainesville, Florida 32608. E-mail: rosenal{at}peds.ufl.edu.

Context: The need for the least ambiguous terminology for disorders affecting IGF-I production and action has become necessary with identification of defects at various steps in the GH-IGF-I axis and the promotion of new indications for and modalities of growth therapy. No generally agreed-upon or consensus-derived classification exists.

Objective: Our objective was to designate all disorders affecting IGF-I production and action by their discrete location, as is already done with the defects in pituitary differentiation factors, avoiding imprecise and ambiguous terminology.

Conclusions: We propose a pragmatic classification that is a precise listing of specific disorders sequentially following the GH-IGF-I axis, using their accepted designations, and the abolition of nonspecific or ambiguous terminology. This concept permits ready insertion of new discoveries.

This article has been cited by other articles:

				P. F. Collett-Solberg, M. Misra, and on behalf of the Drug and Therapeutics Committee o The Role of Recombinant Human Insulin-Like Growth Factor-I in Treating Children with Short Stature J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 10 - 18. [Abstract] [Full Text] [PDF]

				H. M. Domene, P. A. Scaglia, A. Lteif, F. H. Mahmud, S. Kirmani, J. Frystyk, P. Bedecarras, M. Gutierrez, and H. G. Jasper Phenotypic Effects of Null and Haploinsufficiency of Acid-Labile Subunit in a Family with Two Novel IGFALS Gene Mutations J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4444 - 4450. [Abstract] [Full Text] [PDF]

				L. L. Levitsky Defining the Role of IGF-I Therapy for Short Children J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 813 - 814. [Full Text] [PDF]